Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Biogen (BIIB) Takeover 'Makes Sense' - Leerink Partners
August 3, 2016 7:38 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Porges said while they have no information to confirm the suggestions that Merck (MP) and Allergan (OP) are among the potential suitors, it certainly makes sense to us.
"In our recent notes we have suggested... More
Tecfidera IP the Major Risk of Biogen (BIIB) Takeout - Baird
August 3, 2016 7:17 AM EDTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Skorney commented, "Though we are not surprised that takeout discussions are taking place, we question the... More
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
August 2, 2016 3:41 PM EDTBiogen (NASDAQ: BIIB) could be worth $375-$475/share in a takeover RBC Capital's Michael Yee said following reports from the WSJ the company has attracted takeover... More
Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:49 PM EDT)
Biogen (Nasdaq: BIIB) attracted takeover interest from Allergan (NYSE: AGN) and Merck (NYSE: MRK), according to Dow Jones, citing sources. The two companies reportedly... More
